In vivo studies using anti-TIM-3 monoclonal antibodies have shown that it is possible to effectively inhibit tumor growth by restoring effector T cell function and reducing the recruitment of myeloid-derived suppressor cells to tumor microenvironment in a CXCL1-dependent manner [105]. The gene discussed is CXCL1; the disease is neoplasm.